Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: DXC stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at DXC's multiple
Needs EPS (TTM) is negative, DXC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXC FY 2026 (ended Mar 31, 2026) · VNDA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
DXC TECHNOLOGY COMPANY · implied price per share
Bear
$56.24
Base
$66.17
Bull
$76.09
VANDA PHARMACEUTICALS INC. · implied price per share
Bear
-$5.92
Base
-$6.96
Bull
-$8.01
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.12x
0.24x
Net debt / EBITDA
Leverage against operating earnings
0.83x
0.82x
Cash and equivalents
Liquid reserves on the balance sheet
$1.74B
$185.77M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
DXC vs ACN
INTERNATIONAL BUSINESS MACHINES CORP
DXC vs IBM
COGNIZANT TECHNOLOGY SOLUTIONS CORP
DXC vs CTSH
EPAM Systems, Inc.
DXC vs EPAM
Genpact LTD
DXC vs G
UNISYS CORP
DXC vs UIS
SUPERNUS PHARMACEUTICALS, INC.
DXC vs SUPN
CATALYST PHARMACEUTICALS, INC.
DXC vs CPRX
Harmony Biosciences Holdings, Inc.
DXC vs HRMY
ELI LILLY & Co
DXC vs LLY
INCYTE CORP
DXC vs INCY
Sarepta Therapeutics, Inc.
DXC vs SRPT
$3.30B
$78.18M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
